B. Nashan, R. Moore, P. Amlot, A. G. Schmidt, K. Abeywickrama, J. P. Soulillou: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. In: The Lancet. 350(9086), 25. Okt 1997, S. 1193–1198. Erratum in: Lancet. 350(9089), 15. Nov 1997, S. 1484. PMID 9652559.
J. R. Thistlethwaite Jr, B. Nashan, M. Hall, L. Chodoff, T. H. Lin: Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group. In: Transplantation. 70(5), 15. Sep 2000, S. 784–790. PMID 11003358.
A. C. Webster, L. P. Ruster, R. McGee, S. L. Matheson, G. Y. Higgins, N. S. Willis, J. R. Chapman, J. C. Craig: Interleukin 2 receptor antagonists for kidney transplant recipients. In: Cochrane Database Syst Rev. (1), 20. Jan 2010, Art. Nr. CD003897. Review. PMID 20091551.
T. J. Creed u. a.: Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. In: Aliment Pharmacol Ther. 23(10), 15. Mai 2006, S. 1435–1442. PMID 16669958.
